Clinical Trial Update: A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. [Phase 4]

View source ↗

Summary

Phase 4 study evaluating dupilumab for airway inflammation in adults with chronic obstructive pulmonary disease; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Sanofi | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: RECRUITING